Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.
Mary W. Chang, MD
Advertisement
Mary W. Chang, MD, is a pediatric dermatologist and associate professor of dermatology and pediatrics at the University of Wisconsin and UConn Health in Madison.
Articles by Mary W. Chang, MD
Advertisement
Latest Updated Articles
How Ruxolitinib’s Expanded Indication Will Impact Pediatric Patients With ADPublished: September 29th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
